Source-grounded facts extracted from Bausch Health Companies Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michael Goettler resigned as Director at Bausch Health Companies Inc..
“On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.”
Bausch Health Companies Inc. shareholders approved Appointment of the Independent Registered Public Accounting Firm at the 2026-05-19 meeting.
“The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2027 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.”
Bausch Health Companies Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-19 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.”
Bausch Health Companies Inc. shareholders approved Election of Directors at the 2026-05-19 meeting.
“The shareholders elected the following individuals to the Company’s Board of Directors, including Eiry W. Roberts, M.D., who was elected as a new director, to serve until the close of the Company’s 2027 Annual Meeting of Shareholders, until their successors are duly elected or appointed, or until such director’s earlier resignation or removal:”
Bausch Health Companies Inc. reported financial results for the quarter ended March 31, 2026.
“Bausch Health Companies Inc. (the "Company") issued a press release announcing results of operations for the quarter ended March 31, 2026 and certain other financial information as of and for the quarter ended March 31, 2026.”
Bausch Health Companies Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank (effective 2026-01-02).
“On January 2, 2026, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc., entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022”
Bausch Health Companies Inc. amended term loan of $2,802,125,000 with JPMorgan Chase Bank, N.A. at (i) 3.75% per annum for Replacement Term Loans with an interest rate determined maturing January 15, 2031.
“The Fourth Amendment provides for a new $2,802,125,000 tranche of term loans maturing in 2031 (the "Replacement Term Loans"), the proceeds of which were used to refinance all of Bausch + Lomb’s outstanding term B loans due 2031 (the "Third Amendment Term Loans") and term B loans due 2028 (the "First Incremental Term Loans").”
Bausch Health Companies Inc. incurred senior notes of €675,000,000 aggregate principal amount with Citibank, N.A. at three-month EURIBOR (with a 0% floor) plus 3.875% per year maturing January 15, 2031.
“completed the previously announced offering of €675,000,000 aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”).”
Jean-Jacques Charhon changed role as Chief Financial Officer and Chief Accounting Officer at Bausch Health Companies Inc..
“until a permanent replacement is in place, at the time that Mr. Barresi ceases to be the Chief Accounting Officer, Jean-Jacques Charhon, who is currently serving as the Company’s Executive Vice President and Chief Financial Officer, will assume the additional role of Chief Accounting Officer.”
John S. Barresi resigned as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..
“On May 9, 2025, John S. Barresi informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Senior Vice President, Controller and Chief Accounting Officer of the Company.”
Bausch Health Companies Inc. incurred senior notes of $4.4 billion at 10.000% maturing April 15, 2032.
“completed its previously announced private offering (the “Offering”) of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032”
John S. Barresi changed role as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..
“John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.”
Jean-Jacques Charhon was appointed as Executive Vice President and Chief Financial Officer at Bausch Health Companies Inc..
“On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.”
Bausch Health Companies Inc. shareholders approved Appointment of the Independent Registered Public Accounting Firm at the 2024-05-14 meeting.
“The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2024 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration. For Withheld 252,834,132 10,389,131”
Bausch Health Companies Inc. shareholders approved Advisory Vote on Executive Compensation at the 2024-05-14 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement. For Against Abstain Broker Non-Votes I 78,660,733 5,195,531 8,435,696 70,931,303”
Bausch Health Companies Inc. shareholders approved Election of Directors at the 2024-05-14 meeting.
“The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2025 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: Name For Withheld Broker Non-Votes Thomas J. Appio 181,373,219 10,918,741 70,931,303 Christian A. Garcia 181,143,285 11,148,675 70,931,303 Brett M. Icahn 170,144,670 22,147,290 70,931,303 Sarah B. Kavanagh 180,316,464 11,975,496 70,931,303 Frank D. Lee 173,147,642 19,144,318 70,931,303 Steven D. Miller 177,700,669 14,591,291 70,931,303 Richard C. Mulligan, Ph.D. 175,256,854 17,035,106 70,931,303 John A. Paulson 179,422,691 12,869,269 70,931,303 Robert N. Power 173,228,670 19,063,290 70,931,303 Amy B. Wechsler, M.D. 181,626,477 10,665,483 70,931,303”
Bausch Health Companies Inc. reported financial results for the quarter and the year ended December 31, 2023.
“Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2023”
Thomas W. Ross, Sr. departed as Director at Bausch Health Companies Inc..
“On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.”
Russel C. Robertson departed as Director at Bausch Health Companies Inc..
“On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.”
Bausch Health Companies Inc. reported financial results for the quarter ended September 30, 2023.
“On November 2, 2023, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended September 30, 2023 and certain other financial information as of and for the quarter ended September 30, 2023.”
Bausch Health Companies Inc. completed an acquisition involving Novartis Pharma AG and Novartis Finance Corporation (closed 2023-09-29).
“On September 29, 2023, Bausch + Lomb completed the Acquisition pursuant to the terms and conditions of the previously announced Stock and Asset Purchase Agreement”
Bausch Health Companies Inc. incurred term loan of $500,000,000 of new term loans with Bausch + Lomb Corporation at at a rate per annum equal to, at the borrower’s option, either (a) a base rate d maturing September 29, 2028.
“On September 29, 2023, Bausch + Lomb entered into an amendment (the “First Incremental Amendment”) to the credit and guaranty agreement, dated as of May 10, 2022 (the “Credit Agreement,” and as amended by the First Incremental Amendment, the “Amended Credit Agreement”), by and among Bausch + Lomb, certain subsidiaries of Bausch + Lomb as subsidiary guarantors, the lenders party thereto, Citibank, N.A., in its capacity as collateral agent, Goldman Sachs Bank USA, in its capacity as term facility administrative agent, and JPMorgan Chase Bank, N.A., in its capacity as first incremental term facility administrative agent, pursuant to which Bausch + Lomb borrowed $500,000,000 of new term loans (the “First Incremental Term Loans”).”
Bausch Health Companies Inc. incurred senior notes of $1,400,000,000 aggregate principal amount with Bausch + Lomb Corporation at 8.375% maturing October 1, 2028.
“On September 29, 2023, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc. (the “Company”), completed its previously announced offering of $1,400,000,000 aggregate principal amount of its 8.375% Senior Secured Notes due 2028 (the “Notes”).”
Bausch Health Companies Inc. entered into First Incremental Amendment to Bausch + Lomb Credit Agreement with Citibank, N.A., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A. valued at $500,000,000 (effective 2023-09-29).
“On September 29, 2023, Bausch + Lomb entered into an amendment (the “First Incremental Amendment”) to the credit and guaranty agreement, dated as of May 10, 2022 (the “Credit Agreement,” and as amended by the First Incremental Amendment, the “Amended Credit Agreement”), by and among Bausch + Lomb, certain subsidiaries of Bausch + Lomb as subsidiary guarantors, the lenders party thereto, Citibank, N.A., in its capacity as collateral agent, Goldman Sachs Bank USA, in its capacity as term facility administrative agent, and JPMorgan Chase Bank, N.A., in its capacity as first incremental term facility administrative agent, pursuant to which Bausch + Lomb borrowed $500,000,000 of new term loans (the “First Incremental Term Loans”).”
John S. Barresi was appointed as Interim Chief Financial Officer at Bausch Health Companies Inc..
“John S. Barresi, who is currently serving as the Company’s Senior Vice President, Controller and Chief Accounting Officer, will assume the additional role of interim Chief Financial Officer.”
Tom Vadaketh resigned as Executive Vice President, Chief Financial Officer at Bausch Health Companies Inc..
“Tom Vadaketh informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Executive Vice President, Chief Financial Officer of the Company.”
Bausch Health Companies Inc. reported financial results for the quarter ended June 30, 2023.
“On August 3, 2023, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended June 30, 2023 and certain other financial information as of and for the quarter ended June 30, 2023.”
Bausch Health Companies Inc. incurred revolving credit of $600 million with GLAS USA LLC (Administrative Agent) and the Lenders from time to time party thereto at one month Term SOFR plus 6.65% maturing January 28, 2028.
“The Credit Agreement provides for a $600 million revolving credit facility (the “Revolving Credit Facility”), subject to certain borrowing base tests, which matures on January 28, 2028. Loans under the Revolving Credit Facility bear interest at a rate equal to the sum of one month Term SOFR plus 6.65%.”
Bausch Health Companies Inc. shareholders approved Appointment of the Independent Registered Public Accounting Firm at the 2023-05-16 meeting.
“The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2024 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration. For Withheld 260,531,419 2,470,470”
Bausch Health Companies Inc. shareholders approved Advisory Vote on Frequency of Future Advisory Votes on Executive Officer Compensation at the 2023-05-16 meeting.
“The shareholders approved, on a non-binding advisory basis, the frequency of the shareholder vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Proxy Statement. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 190,477,720 616,376 2,187,370 499,158 69,221,265”
Bausch Health Companies Inc. shareholders approved Advisory Vote on Executive Officer Compensation at the 2023-05-16 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Proxy Statement. For Against Abstain Broker Non-Votes 178,033,723 15,117,579 629,322 69,221,265”
Bausch Health Companies Inc. shareholders approved Election of Directors at the 2023-05-16 meeting.
“The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2024 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: Name For Withheld Broker Non-Votes Thomas J. Appio 190,930,071 2,850,553 69,221,265 Brett M. Icahn 169,686,359 24,094,265 69,221,265 Sarah B. Kavanagh 189,301,790 4,478,834 69,221,265 Steven D. Miller 181,093,705 12,686,919 69,221,265 Dr. Richard C. Mulligan 174,330,012 19,450,612 69,221,265 John A. Paulson 182,711,655 11,068,969 69,221,265 Robert N. Power 183,421,864 10,358,760 69,221,265 Russel C. Robertson 189,249,474 4,531,150 69,221,265 Thomas W. Ross, Sr. 190,210,369 3,570,255 69,221,265 Amy B. Wechsler, M.D. 190,174,239 3,606,385 69,221,265”
Bausch Health Companies Inc. reported financial results for the quarter ended March 31, 2023.
“On May 4, 2023, Bausch Health Companies Inc. (the "Company") issued a press release announcing results of operations for the quarter ended March 31, 2023 and certain other financial information as of and for the quarter ended March 31, 2023.”
Argeris Karabelas retired as Director at Bausch Health Companies Inc..
“On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).”
Richard De Schutter retired as Director at Bausch Health Companies Inc..
“On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).”
Bausch Health Companies Inc. reported financial results for the quarter and the year ended December 31, 2022.
“On February 23, 2023, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2022”
Bausch Health Companies Inc. reported financial results for the quarter ended September 30, 2022.
“On November 3, 2022, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended September 30, 2022 and certain other financial information as of and for the quarter ended September 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.”
John A. Paulson was appointed as Chairperson of the Board at Bausch Health Companies Inc..
“Also on June 23, 2022, the Company announced the Board’s appointment of John A. Paulson to the Board to fill the resulting vacancy, effective upon Mr. Papa’s resignation.”
Joseph C. Papa resigned as Director at Bausch Health Companies Inc..
“On June 23, 2022, Bausch Health Companies Inc. (“Bausch Health” or the “Company”) announced that Joseph C. Papa resigned from the Company’s Board of Directors (the “Board”), effective immediately.”
Robert Spurr departed as President, U.S. Businesses at Bausch Health Companies Inc..
“On June 1, 2022, Bausch Health Companies, Inc. (the “Company”) decided to eliminate the position of President, U.S. Businesses, currently held by Robert Spurr, effective June 10, 2022.”
John S. Barresi was appointed as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..
“On May 24, 2022, the Board of Directors of Bausch Health Companies Inc. (“Company”) appointed John S. Barresi, 49, as the Company’s Senior Vice President, Controller and Chief Accounting Officer.”
Tom Vadaketh was appointed as Chief Financial Officer at Bausch Health Companies Inc..
“On January 3, 2022, Tom Vadaketh will join Bausch Health from eResearch Technology Inc., and will serve as the Chief Financial Officer of the Company’s pharmaceutical business and, in connection with Mr. Eldessouky’s appointment as Chief Financial Officer of Bausch + Lomb at the time of the IPO, Mr. Vadaketh will be appointed as Chief Financial Officer of Bausch Health, effective as of the IPO Closing Date.”
Sam Eldessouky departed as Chief Financial Officer at Bausch Health Companies Inc..
“Sam Eldessouky, the current Chief Financial Officer of Bausch Health, will become Chief Financial Officer of Bausch + Lomb, effective as of the closing of the initial public offering of Bausch + Lomb”
Seana Carson was appointed as General Counsel at Bausch Health Companies Inc..
“In connection with Christina Ackermann’s Bausch + Lomb appointment, Seana Carson, Senior Vice President of Legal, will be appointed General Counsel of Bausch Health, effective as of the IPO Closing Date.”
Joseph Gordon departed as other_named_officer at Bausch Health Companies Inc..
“Joseph Gordon will also transfer with Bausch + Lomb, effective as of the IPO Closing Date, where he will lead Bausch + Lomb’s global consumer, vision care and surgical businesses as well as the EMEA ophthalmology pharmaceutical business.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.